Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
National Institutes of Health Clinical Center (CC)
Genmab
Sotio Biotech Inc.
National Institutes of Health Clinical Center (CC)
A2 Biotherapeutics Inc.
Zhejiang University
National Institutes of Health Clinical Center (CC)
Azienda Ospedaliero-Universitaria di Parma
A2 Biotherapeutics Inc.
Verismo Therapeutics
University of Nebraska
Lumicell, Inc.
Perspective Therapeutics
Seagen Inc.
Novartis
NeoTX Therapeutics Ltd.
Actym Therapeutics, Inc.
TCR2 Therapeutics
TCR2 Therapeutics
Incyte Corporation
Numab Therapeutics AG
A2 Biotherapeutics Inc.
Medicenna Therapeutics, Inc.
Ascentage Pharma Group Inc.
University of Pennsylvania
Mayo Clinic
Deciphera Pharmaceuticals, LLC
Aminex Therapeutics, Inc.
Taproot Health
Travera Inc
Aromics Therapeutics
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
UTC Therapeutics Inc.
Memorial Sloan Kettering Cancer Center
NGM Biopharmaceuticals, Inc
Centre Hospitalier Universitaire Vaudois
Multitude Therapeutics Inc.
Candel Therapeutics, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Incyte Corporation
Augusta University
AbbVie
AbbVie
MacroGenics
Incyte Corporation
Oslo University Hospital